Old API Wind-down Ltd.

ARLZQ

CA03852X1006

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2019	Old API Wind-Down Ltd. Announces Management Changes	CI
2019	Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd	CI

Aralez Pharmaceuticals Inc. Appoints James L. Hall as General Manager of Tribute, Effective May 16, 2016

May 10, 2016 at 08:00 am EDT

On April 19, 2016, Aralez Pharmaceuticals Inc. announced that James L. Hall will be appointed as the General Manager of Tribute effective May 16, 2016.

Latest news about Old API Wind-down Ltd.

Old API Wind-Down Ltd. Announces Management Changes	19-05-30	CI
Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd	19-02-06	CI
Aralez Pharmaceuticals Inc. Announces Management Changes	19-01-18	CI
Nuvo Pharmaceuticals Inc. completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc..	18-12-30	CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Composite Index	18-08-20	CI
Aralez Pharmaceuticals Inc. Announces the Resignation of Seth A. Rudnick, Neal F. Fowler and Rob Harris as Directors	18-08-14	CI
Nuvo Pharmaceuticals Inc. signed a letter of intent to acquire Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. for $62.5 million.	18-08-09	CI
Aralez Pharmaceuticals Inc. Announces Resignation of James Tursi as Chief Medical Officer, Effective from August 2, 2018	18-07-26	CI
Aralez Pharmaceuticals Inc. Enters into an Amendment to that Certain Second Amended and Restated Facility Agreement with Deerfield Partners, L.P	18-06-29	CI
Transcript : Aralez Pharmaceuticals Inc., Q1 2018 Earnings Call, May 08, 2018	18-05-08
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-08	CI
Aralez Pharmaceuticals Inc. Announces Resignation of Mark Glickman as Chief Commercial Officer, Effective on March 30, 2018	18-03-21	CI
Aralez Pharmaceuticals Inc. Appoints Michael Kaseta as Chief Financial Officer	18-03-14	CI
Transcript : Aralez Pharmaceuticals Inc., Q4 2017 Earnings Call, Mar 13, 2018	18-03-13
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal Year 2018	18-03-13	CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Biotechnology Index	17-12-15	CI
Aralez Pharmaceuticals Inc. Announces Executive Changes	17-11-30	CI
Transcript : Aralez Pharmaceuticals Inc., Q3 2017 Earnings Call, Nov 09, 2017	17-11-09
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Revises Earnings Guidance for the Year Ending December 31, 2017 and provides Preliminary Guidance for Full Year Ending December 31, 2018	17-11-09	CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from S&P Global BMI Index	17-09-18	CI
Transcript : Aralez Pharmaceuticals Inc., Q2 2017 Earnings Call, Aug 09, 2017	17-08-09
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Revises Earnings Guidance for the Full Year 2017	17-08-09	CI
Aralez Pharmaceuticals Inc. Announces National Commercial Launch of Zontivity in US	17-06-07	CI
Aralez Pharmaceuticals Inc. Announces Resignation of Jason M. Aryeh as Board Member	17-06-07	CI
Transcript : Aralez Pharmaceuticals Inc., Q1 2017 Earnings Call, May 09, 2017	17-05-09

Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OLD API WIND-DOWN LTD.	-.--%	0
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

Old API Wind-down Ltd.

Equities

ARLZQ

CA03852X1006

Pharmaceuticals

Aralez Pharmaceuticals Inc. Appoints James L. Hall as General Manager of Tribute, Effective May 16, 2016

Latest news about Old API Wind-down Ltd.

Chart Old API Wind-down Ltd.

Company Profile

Sector Other Pharmaceuticals